

Screening Phase
Screening days 35
Treatment Phase
Treatment
Cohort 1: 28-day cycle up to 2 years[c,d]
Cohort 2: 28-day cycle up to 2 years*
Cohort 3: Discontinued if PR/CR not observed ≤ 3 months
NMIBC patients who have recurred after BCG therapy[a]
Screening for FGFR mutations/ fusions on tumor tissue
Cohort 1: HR-NMIBC Papillary only (n=240)
Cohort 2: HR-NIMBC CIS with/without papillary disease (n=20)
Cohort 3: IR-NMIBC Marker Lesion after incomplete TUR (n=20)
Randomization 2:1
ERDA
IC[b]
ERDA
ERDA
Cohort 1: Primary Endpoint RFS
Cohort 2: Exploratory Endpoint CR rate at 6 months
Cohort 3: Exploratory Endpoint CR rate at 3 months
Safety visit – Day 30
Disease assessment follow up
Survival follow up – every 12 weeks

FIG. 1



Starting Dose
6 mg QD, continuous
Assess PO4 at the end of Cycle 1 treatment period (C2D1)
PO4<5.5 mg/dL and
No significant toxicity
PO4 5.5 mg/dL to 6.99 mg/dL and
No significant toxicity
PO4≥7 mg/dL
or
Presence of other toxicity
Up-titrate to
8 mg QD, continuous
Remain at
6 mg QD, continuous
Remain at
6 mg QD, continuous and refer to Table 7 for serum PO4 toxicity management

FIG. 2